When: CYTK ruling, Eliquis IRA Medicare final pricing, Iberdomide regulatory milestones, Camzyos adolescent HCM FDA decision

Then: Monitor for 5-10% one-day move risk; reassess positioning accordingly

HOLD existing exposure, collect dividend carry, re-engage on confirmation after Q3 earnings or 200 SMA retest with bullish reversal signals

• 200 SMA structural support sits at 58.67; ATR coiling resolves to downside 60-65% of the time historically, not a contrarian green light
• MACD histogram widened negative from negative 0.14 to negative 0.16 on October 1st with signal re-accelerating lower two days ago
• RSI at 39.14 is approaching oversold but not oversold; BMY already tapped 35.29 on September 24 and bounced to 50.29 before rolling over again, making lower highs in both price and RSI
• Forward PE 9.3 times prices in consensus EPS of 6.56 against current price of 61.46, but consensus may embed overly optimistic patent-cliff assumptions; PE re-rating from 9.3 to 7 on EPS cut to 5.50-6.00 creates 25% drawdown on multiple alone
• Suggested stop discipline is 58.00 rather than 57.50 to honor structural support at 200 SMA (58.67)
• Q3 EPS of 1.50-1.65 is correct arithmetic but does not eliminate binary risk; a miss is not priced while a beat is partially priced
• Volume on recent decline was 10.7 million shares with multiple lower highs and lower lows indicating institutional selling, not accumulation
• Hold existing exposure and collect 4.1% yield rather than averaging into confirmed downtrend; entry triggers are breakout above 63.49 on expanding volume with MACD turning up, or 200 SMA hold with bullish reversal candle and RSI divergence

→ vs aggressive: Claims 200 SMA retest wait is 'missing the move' but post-decline volatility compression resolves to downside 60-65% of the time per the technical report—the base rate is bearish, not a coin flip opportunity

→ vs aggressive: Frames 57.50 stop as 'betting Bristol-Myers will implode 6.5%' but the stop acknowledges structural support at 200 SMA (58.67); beta 0.23 means slower moves down, not immunity—BMY traded at 42.52 on its 52-week low

→ vs aggressive: Calls RSI 39.14 'approaching oversold' and therefore a buy signal, but approaching is not oversold; RSI made a lower high while price made a lower high, which is textbook bearish momentum continuation, not a buying setup

→ vs aggressive: Cites forward PE 9.3 times as compelling while ignoring that consensus EPS of 6.56 likely embeds overly optimistic patent-cliff assumptions; the trader's own thesis flags this risk, making a PE re-rating to 7 on EPS revision lower a 25% multiple drawdown before price erosion

→ vs aggressive: Correctly notes Q3 EPS of 1.50-1.65 but ignores binary risk asymmetry—a miss is not priced while a beat is partially priced, and BMY can drop 4-6% in a day on a defensive name with low volume

→ vs aggressive: Conflates hold and add decisions; 4.1% yield supports existing holders but is not a reason to add new capital where momentum, MACD, and medium-term trend all point down

HOLD; initiate small starter position (15-25% of intended add size) at 61.46 with stop at 58.00; add on 200 SMA test with confirmed reversal candle and RSI bullish divergence; add final tranche post-Q3 earnings on beat with raised guidance

• Forward PE of 9.3x is not expensive; deleveraging is real; Q2'26 print of 1.62 was best in years; beta 0.23 means downside is structurally capped
• RSI at 39.14 is NOT a buy signal—'approaching oversold' and 'is oversold' are different; BMY tapped 35.29 on September 24, bounced to 50.29, then rolled over (failed bounce)
• MACD histogram widened negative on October 1st from negative 0.14 to negative 0.16; this is fresh re-acceleration, not noise
• If forward EPS revised down to 5.50 or 6.00, even at 9.3x the stock re-prices; a 6.56 forward estimate cut to 5.80 against 61.46 price implies 12% drawdown before multiple compression
• 200 SMA has risen 11% in three months; if price retests 58.67, the level itself is moving higher—might be 59.50 or 60.00 by then
• 25% drawdown scenario from multiple compression to 7x PE is an extreme tail case; mega-cap pharma with $13B free cash flow, 4% yield, buyback program doesn't trade at 7x absent credit crisis or pipeline failure
• Stop placement at 58.00 versus 57.50 is functionally identical—both below 200 SMA, roughly 1.5 to 2 ATRs below current price
• Total blended cost basis will be somewhere between 59 and 62 depending on add timing, with first add having tight stop and later adds trailing the structure

→ vs aggressive: RSI at 39.14 is NOT a buy signal; aggressive analyst mischaracterizes the indicator and treats a lagging indicator that printed 50 and rolled over as confirming bullish accumulation when it is not

→ vs aggressive: MACD re-widened negative on October 1st from negative 0.14 to negative 0.16; this is fresh data, not noise or anchored to past; cannot dismiss momentum deterioration in the most recent session

→ vs aggressive: If forward EPS gets revised down to 5.50 or 6.00, which the trader's own thesis flags as risk, then even at 9.3x the stock re-prices; cannot simultaneously argue forward EPS is conservative AND ignore revision risk

→ vs conservative: Post-decline volatility compression resolves to downside 60-65% of time is an unconditional base rate, not a forecast; in a name with 0.23 beta, low recession probability, 4.1% yield, and rising 200 SMA, conditional probability of downside resolution is almost certainly lower

→ vs conservative: 25% drawdown scenario from multiple compression to 7x PE is an extreme tail case requiring 2008-style or 2020-style conditions; implied probability in next 4 weeks is essentially zero; this constructs a straw man to justify inaction

→ vs conservative: Whether stop is 58.00 or 57.50 is functionally identical; both below 200 SMA, roughly 1.5 to 2 ATRs below current price; 117 basis point difference is not the difference between survival and ruin